The treatment protocol for the original study has previously been described in detail (11 (link)). In summary, the USL-bearing esophagus was treated with one of four circumferential RFA regimens (BARXX360 system, Medtronic) at baseline (Supplementary Table 1 ) and sustainable tattoos were placed at the most proximal and distal edges to identify the treatment area (TA). Subsequently patients underwent endoscopies at 3-month intervals with biopsies and focal RFA (BARRX90, 3×12J/cm2, Medtronic) for persisting USLs, until CR was achieved. All patients underwent a 12 month endoscopy with Lugol’s staining and biopsies to assess the primary endpoint of the original study (i.e. the proportion of patients with a complete remission at 12 months).
Barxx360 system
Manufactured by Medtronic
The BARXX360 system is a lab equipment product from Medtronic. It is designed to perform specific laboratory functions. A detailed and unbiased description of the core function of this product cannot be provided while maintaining the specified criteria.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using barxx360 system
1
Circumferential RFA for Esophageal USL
2
Endoscopic Resection and Ablation for ESCN
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Experienced endoscopists in CICAMS conducted all endoscopic procedures. All preoperative ESCN lesions with HGIN or worse histologic grade in biopsy specimens that met the Japan Esophageal Society guideline or the European Society of Gastrointestinal Endoscopy (ESGE) guidelines received ER (ESD or EMR) (14 (link), 19 (link)). The ESD/EMR procedures included Lugol’s iodine staining, marking, submucosal injection, submucosal dissection/mucosal incision, and wound treatment (7 (link), 8 (link)). The ER specimens were examined by at least two experienced pathologists based on the Japanese Classification of Esophageal Cancer (14 (link), 20 (link), 21 (link)).
However, the multiple LVLs containing LGIN outside the resected lesion were radiofrequency ablated through the Barrx™ Ablation System (Medtronic, Sunnyvale, CA, USA). The multiple LVLs of which the range was more than 3/4 of the circumference were treated with circumferential RFA regimens (BARXX360 system), while the scattered multiple LVLs were dealt with focal RFA (BARRX90, 3 × 12 J/cm2; Medtronic). The locations of all lesions and all treatment area (TA) (both ER and RFA) were determined by their distance from the incisor and their clock position on the circumferential esophagus. All data were recorded in the endoscopic reports.
However, the multiple LVLs containing LGIN outside the resected lesion were radiofrequency ablated through the Barrx™ Ablation System (Medtronic, Sunnyvale, CA, USA). The multiple LVLs of which the range was more than 3/4 of the circumference were treated with circumferential RFA regimens (BARXX360 system), while the scattered multiple LVLs were dealt with focal RFA (BARRX90, 3 × 12 J/cm2; Medtronic). The locations of all lesions and all treatment area (TA) (both ER and RFA) were determined by their distance from the incisor and their clock position on the circumferential esophagus. All data were recorded in the endoscopic reports.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!